Jerini AG Reaches Agreement to Sell JPT Peptide Technologies GmbH to TheraCode GmbH

07-May-2009 - Jerini AG has reached an agreement to sell its wholly-owned subsidiary, JPT Peptide Technologies GmbH to TheraCode GmbH, Mainz, a wholly-owned subsidiary of BioNTech AG, Mainz. Under the terms of the agreement, TheraCode GmbH will pay Jerini AG a purchase price of approximately € 5 million in ...

Strategic Review of Jerini Assets Completed

13-Oct-2008 - Jerini AG and Shire Deutschland Investments GmbH have completed the strategic review of the assets and programs of Jerini AG, not related to Icatibant (Firazyr®), as referred to in the Offer Document published by Shire Deutschland Investments GmbH on August 13, 2008. The Jerini Supervisory Board ...

Jerini sells onself to british Shire

Jerini AG for an equity purchase price of EUR 328 million

07-Jul-2008 - Shire Limited, the global specialty biopharmaceutical company, announced that Maia Elfte Vermögensverwaltungs-GmbH, to be renamed "Shire Deutschland Investments GmbH", a German indirect subsidiary of Shire Limited, will launch a voluntary public takeover offer for shares in Jerini AG, the ...

Quality Biological and JPT Peptide Technologies announce non-exclusive distribution and marketing agreement

19-Sep-2005 - JPT Peptide Technologies GmbH (JPT) and Quality Biological, Inc. (QBI), a US molecular biology lab supplies and products manufacturer, announced the start of a non-exclusive distribution and marketing agreement for the USA. Within the scope of this agreement, the parties join forces to better ...